TL;DR
This paper introduces the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC), a large multinational consortium of people living with HIV (PLWHIV) to track progress towards Hepatitis C (HCV) elimination. The consortium's initial data merge of over 104,000 participants reveals that while DAA therapy has led to a decline in HCV incidence, challenges remain in treatment uptake and understanding reinfection dynamics.
What Problem Does This Paper Address?
The World Health Organization (WHO) has set ambitious targets to eliminate HCV as a public health threat by 2030, aiming to significantly reduce incidence and mortality. People living with HIV (PLWHIV) are a key population in this effort, as they are disproportionately affected by HCV, experience more rapid liver disease progression, and benefit from regular HIV care for potential HCV screening and treatment. However, understanding the real-world progress towards HCV elimination, especially in this vulnerable group, requires large-scale, longitudinal data that can capture complex factors like treatment uptake, reinfection, and behavioral drivers. Existing single-country cohorts, while valuable, often lack the statistical power to study rare events or make robust cross-country comparisons. InCHEHC aims to bridge this gap by creating a unified dataset to assess progress and inform elimination strategies.
Methods
The InCHEHC consortium was established in 2017, bringing together prospective longitudinal cohorts of PLWHIV from multiple countries. The study utilizes a data harmonization tool based on the established HIV Cohorts Data Exchange Protocol (HICDEP) to ensure consistency across diverse data sources. This approach allows for the pooling of individual-level data, enabling more powerful analyses than individual cohorts could achieve alone. The paper describes the process of data merging, harmonization, and quality control, emphasizing the collection of clinical, behavioral, and mortality data. Sensitivity analyses are planned to account for methodological differences between cohorts.
Datasets
The primary dataset is the InCHEHC pooled dataset, which, as of the first data merge, includes 104,740 participants from 11 cohorts across Australia, Canada, France, The Netherlands, Spain, and Switzerland. Data collection spans from 1987 to 2021. The paper also references the use of the International Classification of Diseases (ICD-9/10) and Coding Causes of Death in HIV (CoDE) for mortality data.
Key Insights and Ideas
- The Power of Collaboration: The formation of a large, multinational consortium like InCHEHC is crucial for addressing complex public health challenges like HCV elimination, especially in key populations like PLWHIV. It allows for the study of rare events and robust cross-country comparisons.
- DAAs are a Game Changer, but Not a Silver Bullet: The introduction of direct-acting antivirals (DAAs) has significantly improved HCV treatment outcomes and contributed to a decline in HCV incidence, aligning with "treatment-as-prevention" strategies.
- Reinfection Remains a Concern: While primary HCV incidence has decreased, reinfection rates, particularly among those who inject drugs, remain a significant challenge and require further investigation.
- Treatment Uptake is Not Universal: Despite the availability of highly effective DAAs, a substantial proportion of PLWHIV with HCV remain untreated, highlighting the need to understand the barriers to care.
- Behavioral Data is Key: Understanding the role of sexual and injecting risk behaviors, as well as alcohol and drug use, is critical for developing targeted interventions to prevent HCV transmission and reinfection.
Key Results
- The first data merge includes 104,740 participants from 11 cohorts, with data collected from 1987 to 2021.
- The median age at enrollment was 38 years.
- While the exact figures are not detailed in the abstract, the paper indicates that the consortium has been used to assess the impact of DAA introduction on HCV incidence, treatment uptake, and reinfection.
- Early findings suggest that DAA treatment has led to a decline in primary HCV incidence, but reinfection incidence has not decreased as dramatically.
- Approximately 5% of individuals who initiated DAA treatment failed to achieve sustained virological response (SVR12+), and a significant proportion (around 30%) remained untreated despite access to DAAs.
Limitations and Future Work
- Geographic Limitation: The current InCHEHC cohorts are primarily from high-income countries, limiting the generalizability of findings to low- and middle-income countries.
- Cohort Heterogeneity: Differences in study design, coverage of the PLWHIV population, and data collection methods across cohorts necessitate careful interpretation of cross-country comparisons.
- Data Availability: While clinical data is comprehensive, detailed behavioral data is only available for a subset of participants, which can limit the ability to fully explore behavioral drivers of HCV outcomes.
- Future Work: The paper highlights several key questions under investigation, including:
- Differences in HCV testing frequency and their impact on diagnosis and reinfection.
- The association between DAA introduction and reductions in HCV-related mortality across countries.
- Sociodemographic, clinical, and behavioral factors driving new HCV reinfections in the DAA era.
- The impact of DAA treatment on liver fibrosis regression.
- Changes in the prevalence of current HCV infections among PLWHIV over time.
- Differences in injection drug use among men who have sex with men living with HIV across countries.
Summary updated